GNNSF:OTC-Genscript Biotech Corporation (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.27

Change

0.00 (0.00)%

Market Cap

USD 2.73B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 39.01B
UCBJF UCB SA

N/A

USD 37.94B
UCBJY UCB SA ADR

N/A

USD 37.34B
GNMSF Genmab A/S

N/A

USD 13.64B
WXIBF WuXi Biologics

N/A

USD 8.99B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 8.93B
IVBIY IVBIY

N/A

USD 7.80B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.48B
ZLDPF Zealand Pharma A/S

N/A

USD 7.14B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.89B

ETFs Containing GNNSF

CHB 0.00 % 1.12 %

N/A

N/A
FCA First Trust China AlphaDE.. 0.00 % 0.80 %

N/A

USD 0.03B
CHIH 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -47.95% 38% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.95% 38% F 22% F
Trailing 5 Years  
Capital Gain -47.30% 68% D+ 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.30% 68% D+ 38% F
Average Annual (5 Year Horizon)  
Capital Gain 12.56% 53% F 56% F
Dividend Return 12.56% 53% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.06% 54% F 41% F
Risk Adjusted Return 16.96% 67% D+ 50% F
Market Capitalization 2.73B 94% A 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector